Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941511 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL1954285 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL10633018 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL868782 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL8031217 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL10427141 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL33526075 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL867932 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL6088399 | 1.00 | NOS3 (0.42) | NOS3NOS1DPP4DPP8DPP9 | |
| SCHEMBL19271810 | 0.98 | NOS3 (0.43) | NOS3NOS1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-110787300-B | Composition containing sodium hyaluronate and preparation and application thereof | 中山万远新药研发有限公司 | 2020-09-22 | — | — | CN | disclosed |
| CN-110787300-A | Composition containing sodium hyaluronate and preparation and application thereof | 中山万远新药研发有限公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-1708765-B1 | BIOCOMPATIBLE POLYMERIZATION ACCELERATORS | SURMODICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8273891-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-8202833-B2 | Coating of polymer containing N-vinyl groups on cells, tissue | SURMODICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8106066-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| EP-0828740-B1 | 2-AZABICYCLO[2.2.1]HEPTANE DERIVATIVES, PREPARATION AND APPLICATION THEREOF | AVENTIS PHARMA SA (FR) | 2001-09-05 | — | — | EP | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
| EP-0424064-B1 | Chiral azabicyloheptanone and a process for their preparation | CHIROSCIENCE LTD (GB) | 1995-02-08 | — | — | EP | disclosed |
| EP-0424064-A1 | Chiral azabicyloheptanone and a process for their preparation | Chiroscience Limited (GB) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | NOS3 3996/4885NOS1 4180/4885DPP4 4080/4885 |
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | NOS3 1685/4885NOS1 1195/4885DPP4 1742/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NOS3 3928/4885NOS1 4063/4885DPP4 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.